Technology Offerings

New Genetic Markers Improve Transplant Rejection Outcomes

In cardiovascular, respiratory, kidney and haematological diseases transplantation remains the most effective long term therapy for patients with advanced organ failure. In addition, hematopoietic stem cell transplantation (HSCT) for the treatment of lymphoproliferative disorders and leukemias has recently become an important mainstay in oncology. There is an urgent need for non-invasive, predictive and diagnostic monitoring to improve outcomes. The global market for transplant diagnostics is projected to grow at 12% CAGR to reach $553 million in 2015.

Further Information: PDF

MBM ScienceBridge GmbH
Phone: (0551) 30724-151

Contact
Dr. Jens-Peter Horst

Comments (0)

Write a comment